The MS-LINK™ Outcomes Study
NCT04735406 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2182
Last updated 2024-08-22
Summary
The Multiple Sclerosis (MS) Leadership and Innovation Network (MS-LINK™) is comprised of networks working cooperatively to advance Multiple Sclerosis (MS) science and improve MS participant outcomes. In this study participants will be followed from the time of consent through the lifetime of the study (currently 3 years), unless the participant chooses to withdraw from the study. Collection of participant's medical history, including MS and treatment history, will be automated through extraction from the participant's electronic medical record (EMR) and other health information systems (for example, radiology). Participants will complete patient-reported outcomes (PROs) and other health-related information digitally. Participating participants will have access to their own data in an ongoing manner via a web-based Participant Portal.
Conditions
Sponsors & Collaborators
-
EMD Serono Research & Development Institute, Inc.
lead INDUSTRY
Principal Investigators
-
Medical Responsible · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-03-24
- Primary Completion
- 2024-01-31
- Completion
- 2024-05-31
Countries
- United States
Study Locations
More Related Trials
-
A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment
NCT00702065 ·Status: COMPLETED
-
Use of a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis.
NCT04595799 ·Status: ACTIVE_NOT_RECRUITING
-
Strengthening Mental Abilities With Relational Training (SMART) in Multiple Sclerosis (MS): A Feasibility Trial
NCT04975685 ·Status: RECRUITING ·Phase: NA
-
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
NCT02845635 ·Status: COMPLETED
-
Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis
NCT01745783 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration
NCT06223074 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
NCT02994121 ·Status: RECRUITING
-
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
NCT00239655 ·Status: TERMINATED ·Phase: PHASE2
-
ATX-MS-1467 in Multiple Sclerosis
NCT01973491 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.
NCT02792231 ·Status: COMPLETED ·Phase: PHASE3
-
Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients
NCT02142764 ·Status: COMPLETED ·Phase: NA
-
Multiple Sclerosis: FutureMS-2 - an Observational Cohort and Scottish Precision Medicine Study
NCT06001138 ·Status: ENROLLING_BY_INVITATION
-
A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
NCT00087529 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
NCT01895335 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
NCT01541618 ·Status: COMPLETED
-
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
NCT05834855 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
NCT02792218 ·Status: COMPLETED ·Phase: PHASE3
-
A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis
NCT01539395 ·Status: WITHDRAWN
-
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
NCT00109161 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis
NCT04749667 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis
NCT02035514 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
NCT01623596 ·Status: COMPLETED ·Phase: PHASE4
-
Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis
NCT01056471 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
NCT01318421 ·Status: TERMINATED ·Phase: PHASE1